Zatosetron
Zatosetron is a serotonin antagonist and reuptake inhibitor (SARI) that was under development by Eisai Co. for the treatment of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). However, the development of Zatosetron was discontinued for unknown reasons.
Pharmacology[edit | edit source]
Zatosetron acts as a potent and selective 5-HT3 receptor antagonist. The 5-HT3 receptors are located on the nerve terminals of the vagus nerve in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The blockade of these receptors prevents the nausea and vomiting caused by chemotherapeutic agents and postoperative complications.
Clinical Trials[edit | edit source]
Zatosetron was in Phase II clinical trials for the treatment of CINV and PONV. However, the development was discontinued after Phase II trials. The reasons for the discontinuation are not publicly disclosed.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
